Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ikervis in DED with severe keratitis
NCT03237936Phase 4Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Mar 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of cyclosporine 2% ophthalmic solution in dry eye disease (DED), keratitis, sponsored by Santen Pharmaceutical. Started Mar 2017; status: completed.
02
Drugs
cyclosporine 2% ophthalmic solution
03
Conditions
dry eye disease (DED)keratitis
Beyond the preview
Go deeper on NCT03237936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03237936.